GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » The Medicines Co (NAS:MDCO) » Definitions » Asset Turnover

The Medicines Co (The Medicines Co) Asset Turnover : 0.00 (As of Sep. 2019)


View and export this data going back to 2000. Start your Free Trial

What is The Medicines Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. The Medicines Co's Revenue for the three months ended in Sep. 2019 was $0.00 Mil. The Medicines Co's Total Assets for the quarter that ended in Sep. 2019 was $926.77 Mil. Therefore, The Medicines Co's Asset Turnover for the quarter that ended in Sep. 2019 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. The Medicines Co's annualized ROE % for the quarter that ended in Sep. 2019 was -4,881.68%. It is also linked to ROA % through Du Pont Formula. The Medicines Co's annualized ROA % for the quarter that ended in Sep. 2019 was -31.94%.


The Medicines Co Asset Turnover Historical Data

The historical data trend for The Medicines Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

The Medicines Co Asset Turnover Chart

The Medicines Co Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.16 0.08 0.04 0.01

The Medicines Co Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of The Medicines Co's Asset Turnover

For the Drug Manufacturers - Specialty & Generic subindustry, The Medicines Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The Medicines Co's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Medicines Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where The Medicines Co's Asset Turnover falls into.



The Medicines Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

The Medicines Co's Asset Turnover for the fiscal year that ended in Dec. 2018 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2018 )/( (Total Assets (A: Dec. 2017 )+Total Assets (A: Dec. 2018 ))/ count )
=6.138/( (872.983+841.686)/ 2 )
=6.138/857.3345
=0.01

The Medicines Co's Asset Turnover for the quarter that ended in Sep. 2019 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2019 )/( (Total Assets (Q: Jun. 2019 )+Total Assets (Q: Sep. 2019 ))/ count )
=0/( (956.273+897.27)/ 2 )
=0/926.7715
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


The Medicines Co  (NAS:MDCO) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

The Medicines Co's annulized ROE % for the quarter that ended in Sep. 2019 is

ROE %**(Q: Sep. 2019 )
=Net Income/Total Stockholders Equity
=-295.976/6.063
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-295.976 / 0)*(0 / 926.7715)*(926.7715/ 6.063)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*152.8569
=ROA %*Equity Multiplier
=-31.94 %*152.8569
=-4,881.68 %

Note: The Net Income data used here is four times the quarterly (Sep. 2019) net income data. The Revenue data used here is four times the quarterly (Sep. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

The Medicines Co's annulized ROA % for the quarter that ended in Sep. 2019 is

ROA %(Q: Sep. 2019 )
=Net Income/Total Assets
=-295.976/926.7715
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-295.976 / 0)*(0 / 926.7715)
=Net Margin %*Asset Turnover
= %*0
=-31.94 %

Note: The Net Income data used here is four times the quarterly (Sep. 2019) net income data. The Revenue data used here is four times the quarterly (Sep. 2019) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


The Medicines Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of The Medicines Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


The Medicines Co (The Medicines Co) Business Description

Traded in Other Exchanges
N/A
Address
8 Sylvan Way, Parsippany, NJ, USA, 07054
The Medicines Company is a pharmaceutical firm that provides products to the U.S. hospital market. The company's primary commercial product, Angiomax, is an anticoagulant drug used in conjunction with aspirin for patients undergoing angioplasty. Medicines recently commercialized a new drug, Cleviprex, which is designed to control blood pressure in intensive-care settings.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Peter Wijngaard officer: Chief Development Officer 8 SYLVAN WAY, PARSIPPANY NJ 07054
Paris Panayiotopoulos director ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Geno J Germano director 5 GIRALDA FARMS, MADISON NJ 07940
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christopher T Cox officer: EVP & Chief Corp. Dev. Officer CADWALADER, WICKERSHAM & TAFT LLP, ONE WORLD FINANCIAL CENTER, NEW YORK NY 10281
Fredric N Eshelman director, officer: Executive Chairman PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Armin M Kessler director
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Hiroaki Shigeta director THE MEDICINES COMPANY, 8 SYLVAN WAY, PARSIPPANY NJ 07054
Stuart A Kingsley officer: President and COO 152 CHESTNUT STREET, WEST NEWTON MA 02465
Robert G. Savage director C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Glenn Sblendorio director, officer: President & CFO 3 TIMES SQAURE, 12TH FLOOR, NEW YORK NY 10036
James E Flynn 10 percent owner, other: Possible Members of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Members of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010